Empagliflozin/Metformin Hydrochloride Tablet 5/850 mg
Empagliflozin 5mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Aju Pharmaceuticals Co., Ltd.
MFDS item code 202201402 · Approved 2022.04.04
Improvement of glycemic control in adults with type 2 diabetes mellitus
This drug is used as a treatment to help effectively control blood glucose levels in adults with type 2 diabetes when combined with dietary and exercise therapy, using a combination of empagliflozin and metformin. Additionally, for patients with type 2 diabetes who have inadequate blood glucose control and a risk of cardiovascular disease, caution is advised regarding the occurrence of cardiovascular events, and professional guidance should be consulted. Overall, this drug helps to improve blood glucose control in diabetes patients.
The recommended dose of this medicine is 1 tablet twice daily. The dose should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each ingredient: empagliflozin 25 mg and metformin 2000 mg. For patients who cannot achieve adequate glycemic control with metformin alone or in combination with other medicines, such as insulin, the recommended dose when taking this medicine is empagliflozin 5 mg twice daily (total daily dose 10 mg) and the patient's current dose of metformin. If empagliflozin 10 mg (total daily dose) is well tolerated and additional glycemic control is needed, the dose may be increased to empagliflozin 25 mg (total daily dose). Patients switching to this medicine from combination therapy with empagliflozin (total daily dose 10 mg or 25 mg) and metformin should receive their previous doses of empagliflozin and metformin. When this medicine is coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia. This medicine should be taken with meals to reduce gastrointestinal adverse reactions associated with metformin. If you miss a dose of this medicine, take it as soon as you remember. However, do not take a double dose at one time; in this case, skip the missed dose. No dose adjustment is necessary in patients with mild renal impairment. Because this medicine contains metformin, it may be used with dose adjustment in patients with an estimated glomerular filtration rate (eGFR) of 45-59 ml/min/1.73m2 or a CrCl of 45-59 ml/min who do not have other conditions that may increase the risk of lactic acidosis. In these patients, the starting dose of metformin is 500 mg or 850 mg once daily; therefore, treatment should be initiated with the individual components, empagliflozin and metformin. The maximum daily dose of metformin hydrochloride that may be given as this medicine is 1000 mg, which may be administered as 500 mg twice daily. Renal function should be carefully monitored every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine should be discontinued immediately. In patients aged 75 years or older, renal function and the risk of volume depletion should be taken into consideration.
This drug helps control blood glucose levels. However, there are specific points to be cautious about when taking this medication. First, there is a rare side effect known as severe lactic acidosis that can occur, which can be very dangerous. Additionally, hypoglycemia can occur when taken with other diabetes medications, so blood glucose levels should be monitored closely. This medication should not be administered to patients with moderate to severe renal impairment, and use should also be avoided in patients with acute kidney issues, severe infections, or heart problems. Patients undergoing examinations requiring iodine contrast media should temporarily halt the medication and resume only after normal kidney function is confirmed post-examination. Regular kidney function tests should be conducted while taking this medication, and particular care is necessary during times of dehydration or severe vomiting and diarrhea that may cause fluid loss. Moreover, when taken with insulin or sulfonylureas, there may be an increased risk of hypoglycemia, necessitating dosage adjustments. This drug can cause gastrointestinal disturbances (diarrhea, vomiting, etc.), urinary tract infections, genital infections, and increased urination. Genital infections can occur frequently, so immediate consultation with healthcare professionals is necessary if symptoms appear. It is safest for pregnant women or those who may become pregnant, as well as breastfeeding women, to avoid using this medication. For elderly patients, considering the commonality of renal function decline, dosage adjustments and regular kidney function monitoring are needed. Alcohol consumption may increase the risk of lactic acidosis, so it is advisable to avoid drinking while on this medication. If sudden weight loss, severe fatigue, difficulty breathing, abdominal pain, or vomiting occur during this treatment, the physician must be notified immediately. Also, symptoms of hypoglycemia include dizziness, cold sweat, and severe hunger, which should be closely monitored. Finally, it is important to consult healthcare professionals regarding the temporary discontinuation of this medication prior to surgery or significant examinations.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to protect it from air and moisture. It is also advisable to avoid storing it in excessively hot or cold locations, and to keep it at room temperature between 1 to 30 degrees Celsius.
White film-coated tablets that are oval, convex on both sides with a yellowish tint
10 tablets/box [10 tablets/PTP*1], 60 tablets/box [10 tablets/PTP*6], 60 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Empagliflozin 5mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Aju Pharmaceuticals Co., Ltd.
CombinationEmpagliflozin 5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 5mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 12.5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 12.5mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 12.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Donggu Bio Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.